Medicine availability within any country is shaped by a network of global and local systems that extend far beyond national borders. In South Africa, as in many other countries, the pharmaceutical supply chain is closely linked to international manufacturing hubs, shipping routes, and trade networks. As a result, global events such as geopolitical conflict, trade restrictions, and large-scale disruptions can influence how medicines move from production sites to patients.
Understanding this relationship is important in explaining why medicine availability can fluctuate, even when local regulatory and procurement systems are functioning as intended.
At the core of the global pharmaceutical system is the production of active pharmaceutical ingredients (APIs), the chemical or biological components that give medicines their therapeutic effect. A significant proportion of APIs used worldwide are manufactured in a relatively small number of countries. This concentration of production creates efficiencies of scale, but it also introduces dependency. When disruptions occur in these regions, the impact can extend across multiple markets simultaneously.
Geopolitical conflict is one such disruption. Conflict can affect manufacturing output directly through damage to infrastructure or indirectly through workforce displacement, energy instability, and restricted access to raw materials. In addition, conflict often leads to trade restrictions, sanctions, or changes in export policies, which can alter the availability of key pharmaceutical inputs.
Shipping and logistics represent another critical point of vulnerability. Medicines and APIs are transported through global shipping networks that rely on stable trade routes and port operations. Disruptions in major shipping corridors, whether due to conflict, congestion, or regulatory controls, can lead to delays in delivery timelines. Even short-term interruptions can have downstream effects, particularly for products that are manufactured on a just-in-time basis or have limited buffer stock.
Currency fluctuations associated with global instability can also influence procurement dynamics. Many pharmaceutical inputs are priced in foreign currencies, and changes in exchange rates can affect the cost of importing both APIs and finished products. While pricing frameworks and procurement contracts may absorb some of this variability, sustained fluctuations can influence supplier behaviour, contract execution, and future tender pricing.
In the South African context, these global factors interact with local systems of procurement, distribution, and stock management. Public sector medicine supply is largely coordinated through national tenders, supported by provincial depots and facility-level distribution. When global supply disruptions affect supplier timelines, this can translate into delays in order fulfilment at the local level.
It is important to note that supply disruptions are rarely attributable to a single factor. Instead, they often reflect a combination of upstream and downstream influences. For example, a delay in API production may coincide with shipping congestion and local distribution challenges, resulting in cumulative impact on availability.
Certain categories of medicines may be more sensitive to global disruption than others. Products that rely on specialised manufacturing processes, limited suppliers, or complex cold chain logistics may be more vulnerable to delays. Similarly, medicines with shorter shelf lives or those requiring frequent resupply may be affected more quickly by interruptions in the supply chain.
To manage these risks, a range of mitigation strategies are typically employed across the pharmaceutical value chain. Manufacturers may diversify sourcing of raw materials across multiple regions to reduce reliance on a single supplier base. Strategic stockholding can provide short-term buffers against supply interruptions, although this approach must be balanced against storage capacity and expiry considerations.
At the procurement level, forecasting plays a central role in anticipating demand and aligning supply. Accurate consumption data allows for more effective planning, particularly in high-burden disease programmes where continuity of treatment is essential. Digital tools that improve visibility of stock levels at depot and facility level can support earlier identification of potential shortages and enable redistribution where necessary.
Regional collaboration is another area of focus. Within the Southern African Development Community (SADC), there are ongoing efforts to strengthen coordination in regulatory review and procurement practices. While these initiatives are primarily aimed at improving efficiency, they can also contribute to more coordinated responses to supply disruptions by facilitating information sharing and aligned decision-making.
It is also relevant to consider that global disruption does not always result in immediate or uniform impact across all products or regions. The extent of the effect depends on factors such as existing stock levels, supplier contracts, and the ability to source alternatives. In some cases, supply chains are able to absorb short-term disruptions without noticeable impact at facility level. In others, prolonged or compounded disruptions may lead to temporary shortages.
From a systems perspective, the relationship between global events and local medicine availability highlights the importance of resilience across the entire supply chain. This includes not only manufacturing and logistics, but also regulatory processes, procurement planning, and inventory management.
In South Africa, ongoing efforts to strengthen supply chain visibility, improve forecasting accuracy, and enhance coordination between stakeholders are part of a broader approach to managing these risks. While global events remain outside the control of any single country, the way in which local systems respond can influence the extent to which disruptions affect patient access.
As global supply chains continue to evolve, the interaction between international developments and domestic healthcare systems will remain a key consideration in ensuring consistent access to medicines. Understanding these dynamics provides context for how availability is shaped and where targeted improvements can support greater stability over time.